MESO · Nasdaq, OTC · CIK 0001345099
MESOBLAST LTD
MESOBLAST LTD’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 16, 2026. In fiscal 2025 (year ended Jun 30, 2025) it reported revenue of $17.2M and net income of -$102.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 3 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- MESOBLAST LTD
- Tickers
- MESO, MEOBF
- SEC Central Index Key (CIK)
- 0001345099
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- MELBOURNE, VICTORIA, Australia
- State or country of incorporation
- Australia
- Fiscal year ends
- June 30
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #2126 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from MESOBLAST LTD’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Jun 30, 2021 | FY2022 ended Jun 30, 2022 | FY2023 ended Jun 30, 2023 | FY2024 ended Jun 30, 2024 | FY2025 ended Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $7.4M | $10.2M | $7.5M | $5.9M | $17.2M |
| Net income | -$98.8M | -$91.3M | -$81.9M | -$88.0M | -$102.1M |
| Diluted EPS | -$0.16 | -$0.13 | -$0.11 | -$0.09 | -$0.08 |
| Total assets | $744.7M | $662.1M | $669.4M | $669.2M | $784.7M |
| Cash and equivalents | $136.9M | $60.4M | $71.3M | $63.0M | $161.6M |
XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
Recent SEC filings
The 40 newest documents filed by or about MESOBLAST LTD, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 16, 2026 | 6-K | Report of a foreign private issuer· period Oct 16, 2026 | Document · Index |
| Oct 15, 2026 | 6-K | Report of a foreign private issuer· period Oct 14, 2026 | Document · Index |
| Oct 13, 2026 | 6-K | Report of a foreign private issuer· period Oct 13, 2026 | Document · Index |
| Sep 24, 2026 | 6-K | Report of a foreign private issuer· period Sep 24, 2026 | Document · Index |
| Aug 27, 2026 | 6-K | Report of a foreign private issuer· period Aug 27, 2026 | Document · Index |
| Aug 27, 2026 | 20-F | Annual report of a foreign private issuer· period Jun 30, 2026 | Document · Index |
| Aug 25, 2026 | 6-K | Report of a foreign private issuer· period Aug 25, 2026 | Document · Index |
| Aug 24, 2026 | 6-K | Report of a foreign private issuer· period Aug 24, 2026 | Document · Index |
| Aug 18, 2026 | 6-K | Report of a foreign private issuer· period Aug 17, 2026 | Document · Index |
| Jul 30, 2026 | 6-K | Report of a foreign private issuer· period Jul 30, 2026 | Document · Index |
| Jul 21, 2026 | 6-K | Report of a foreign private issuer· period Jul 21, 2026 | Document · Index |
| Jul 15, 2026 | 6-K | Report of a foreign private issuer· period Jul 14, 2026 | Document · Index |
| Jul 14, 2026 | 6-K | Report of a foreign private issuer· period Jul 14, 2026 | Document · Index |
| Jul 10, 2026 | 6-K | Report of a foreign private issuer· period Jul 10, 2026 | Document · Index |
| Jul 9, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 7, 2026 | Document · Index |
| Jul 1, 2026 | 6-K | Report of a foreign private issuer· period Jul 1, 2026 | Document · Index |
| Jun 25, 2026 | 6-K | Report of a foreign private issuer· period Jun 25, 2026 | Document · Index |
| Jun 10, 2026 | 6-K | Report of a foreign private issuer· period Jun 10, 2026 | Document · Index |
| Apr 30, 2026 | 6-K | Report of a foreign private issuer· period Apr 30, 2026 | Document · Index |
| Apr 29, 2026 | 6-K | Report of a foreign private issuer· period Apr 29, 2026 | Document · Index |
| Apr 29, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Apr 17, 2026 | 6-K | Report of a foreign private issuer· period Apr 17, 2026 | Document · Index |
| Apr 15, 2026 | 6-K | Report of a foreign private issuer· period Apr 15, 2026 | Document · Index |
| Apr 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 9, 2026 | Document · Index |
| Apr 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 9, 2026 | Document · Index |
| Apr 8, 2026 | 6-K | Report of a foreign private issuer· period Apr 8, 2026 | Document · Index |
| Apr 8, 2026 | 6-K | Report of a foreign private issuer· period Apr 8, 2026 | Document · Index |
| Apr 8, 2026 | 6-K | Report of a foreign private issuer· period Apr 8, 2026 | Document · Index |
| Apr 8, 2026 | 6-K | Report of a foreign private issuer· period Apr 8, 2026 | Document · Index |
| Apr 1, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Apr 1, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Apr 1, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Mar 23, 2026 | 3 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES· period Mar 18, 2026 | Document · Index |
| Mar 23, 2026 | 6-K | Report of a foreign private issuer· period Mar 23, 2026 | Document · Index |
| Mar 18, 2026 | 6-K | Report of a foreign private issuer· period Mar 18, 2026 | Document · Index |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership· period Mar 18, 2026 | Document · Index |
Insider filing activity
3 Form 4 filings appear in MESOBLAST LTD’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
All 61 companies in Biological Products, (No Diagnostic Substances)
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001345099 and XBRL company facts. MESOBLAST LTD on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement